The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Are BTK inhibitors a suitable treatment option for CLL with cardiovascular comorbidities?
Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses using BTK inhibitors (BTKIs) for patients with chronic lymphocytic leukemia (CLL) with cardiovascular comorbidities. Although atrial fibrillation and hypertension are known side effects, Dr Shadman emphasizes that BTKIs can still be used, provided a comprehensive risk assessment is conducted with cardiologists. The choice of BTKI should be carefully considered in this patient subgroup, as current data suggest that rates of atrial fibrillation are lower with acalabrutinib and zanubrutinib than with ibrutinib. Based on findings from the ELEVATE-RR trial (NCT02477696), acalabrutinib is likely a better choice of BTKI than ibrutinib for patients with difficult-to-control hypertension. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
